Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | SVP, Accounting and Fin. Ops. | November 18, 2024 | November 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tenaya Therapeutics, Inc.
Report date November 18, 2024 · Filed November 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,983 |
Reported balance
After 2024-11-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-11-18 · Sale · Disposed 2,258 · Balance 60,983 F1: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2: Includes 45,168 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.
F2: Includes 45,168 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2024 Filed Nov 18, 2024 20:48 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 2,258 | $2.12 | $4,786.96 |
DisclosureSEC source: 0000950170-24-128200 · ownership.xml · nonDerivative · entry 1 Saito Chihiro · CIK 0002034025 · SVP, Accounting and Fin. Ops. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,983 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. F2 · balance_after: Includes 45,168 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 807 | $2.89 | $2,335.86 |
DisclosureSEC source: 0000950170-24-098810 · ownership.xml · nonDerivative · entry 4 Saito Chihiro · CIK 0002034025 · SVP, Accounting and Fin. Ops. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,241 F9 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F10 · balance_after: Includes 55,409 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 654 | $2.89 | $1,893.00 |
DisclosureSEC source: 0000950170-24-098810 · ownership.xml · nonDerivative · entry 3 Saito Chihiro · CIK 0002034025 · SVP, Accounting and Fin. Ops. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,048 F7 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F8 · balance_after: Includes 56,216 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 20:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 902 | $2.89 | $2,610.84 |
DisclosureSEC source: 0000950170-24-098810 · ownership.xml · nonDerivative · entry 2 Saito Chihiro · CIK 0002034025 · SVP, Accounting and Fin. Ops. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,702 F4 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on October 15, 2022. F5 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.79 to $3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F6 · balance_after: Includes 56,870 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:30 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098810 · ownership.xml · nonDerivative · entry 1 Saito Chihiro · CIK 0002034025 · SVP, Accounting and Fin. Ops. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,604 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the total number of shares subject to the restricted stock unit award on November 15, 2024, and 1/4th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 57,772 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.